The aim of this study is to determine the success rates for stopping smoking with varenicline in Germany. The main measure of success will be continuous abstinence from smoking (not a single puff) in the last week of the standard 12 week treatment period. Additional information will be gathered regarding prescribing practices in Germany, smoking history, reasons why smokers quit smoking and re-start smoking, smoking related illnesses and the tolerability of varenicline.
- Legal adult age
- Regular smoker, with main tobacco product smoked being cigarettes, and willing and
motivated to stop smoking
- Evidence of a personally signed and dated Informed Consent document.
- Any subjects considered unsuitable according to the Summary of product characteristics
(SmPC)
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
